Investors have shown a mixed sentiment towards Iovance Biotherapeutics (NASDAQ:IOVA), with options trading revealing 47% bullish and 52% bearish positions. A significant volume of options trades, including both calls and puts, indicates a targeted price range of $10.0 to $25.0 for IOVA. The company, a pioneer in T-cell therapy for solid tumor cancers, is preparing for potential U.S. regulatory approval. Analysts have given IOVA an average target price of $23.0, with ratings ranging from Buy to Market Outperform.